Profile data is unavailable for this security.
About the company
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
- Revenue in GBP (TTM)30.40m
- Net income in GBP-15.56m
- Incorporated2015
- Employees77.00
- LocationShield Therapeutics PLC3rd FlBaltic Business Quarters, Abbott's HillGATESHEAD NE8 3DUnited KingdomGBR
- Phone+44 191 511 8500
- Websitehttps://www.shieldtherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma Group Ltd | 214.08m | -46.69m | 110.33m | 450.00 | -- | 0.5749 | -- | 0.5154 | -1.14 | -1.19 | 5.22 | 4.56 | 0.3828 | 2.57 | 2.42 | 917,797.80 | -8.35 | -15.32 | -11.61 | -20.87 | 61.06 | 53.04 | -21.81 | -64.51 | 1.16 | -- | 0.1003 | -- | 4.44 | -2.04 | 46.58 | -- | -9.26 | -- |
| NDT Pharmaceuticals Inc | -73.26bn | -73.26bn | 111.36m | 1.00 | -- | 0.8486 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Beta Drugs Ltd | 31.20m | 3.76m | 112.18m | 399.00 | 19.70 | 6.27 | 22.64 | 3.60 | 69.72 | 65.19 | 509.33 | 218.94 | 0.986 | 3.64 | 3.48 | 9,665,303.00 | 11.88 | 15.08 | 16.29 | 21.53 | 39.79 | 40.30 | 12.05 | 12.72 | 2.45 | 5.13 | 0.3974 | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| T Man Pharmaceutical PCL | 55.52m | 10.60m | 112.28m | 960.00 | 10.59 | 2.46 | 8.36 | 2.02 | 1.12 | 1.12 | 5.88 | 4.84 | 0.754 | 2.03 | 3.64 | 2,452,049.00 | 14.40 | -- | 33.57 | -- | 47.67 | -- | 19.09 | -- | 0.9128 | 17.38 | 0.3316 | -- | 12.19 | -- | 4.55 | -- | -- | -- |
| Shield Therapeutics PLC | 30.40m | -15.56m | 112.98m | 77.00 | -- | -- | -- | 3.72 | -0.0177 | -0.0177 | 0.0333 | -0.0105 | 0.7624 | 3.98 | 2.12 | 394,854.60 | -39.02 | -60.44 | -131.46 | -78.58 | 48.34 | 50.99 | -51.18 | -212.62 | 0.6922 | -2.50 | 2.22 | -- | 145.93 | 103.70 | 18.36 | -- | 6.51 | -- |
| Ngl Fine Chem Ltd | 36.15m | 2.86m | 113.83m | 456.00 | 39.77 | -- | 26.43 | 3.15 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Botanix Pharmaceuticals Ltd | 2.98m | -44.78m | 114.88m | 1.00 | -- | 2.71 | -- | 38.50 | -0.0466 | -0.0466 | 0.0031 | 0.0415 | 0.0477 | 0.2477 | 3.48 | -- | -71.53 | -50.27 | -81.16 | -56.02 | 36.99 | -- | -1,500.65 | -1,888.17 | 2.87 | -- | 0.2226 | -- | 856.64 | 102.14 | -522.91 | -- | 63.43 | -- |
| Ste Promotion Pharmaceutique du Mghrb SA | 74.46m | 4.58m | 115.02m | -- | 25.09 | 2.49 | 12.51 | 1.54 | 57.20 | 57.20 | 928.99 | 575.64 | 0.7791 | 1.38 | 3.90 | -- | 4.80 | 8.48 | 7.50 | 12.35 | 44.33 | 48.51 | 6.16 | 8.76 | 0.9687 | 16.40 | 0.2975 | -- | 11.57 | 11.46 | -3.05 | 1.14 | 44.62 | -- |
| Karyopharm Therapeutics Inc | 104.42m | -91.30m | 115.10m | 279.00 | -- | -- | -- | 1.10 | -14.58 | -14.58 | 16.69 | -30.94 | 0.9977 | 1.34 | 4.48 | 510,860.20 | -87.24 | -48.75 | -181.85 | -63.64 | 95.93 | 97.09 | -87.43 | -92.03 | 0.9842 | -2.55 | -- | -- | -0.5451 | 28.85 | 46.60 | -- | -7.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 03 Nov 2025 | 64.79m | 6.10% |
| Hargreaves Lansdown Asset Management Ltd.as of 23 Apr 2025 | 62.62m | 5.90% |
| Premier Fund Managers Ltd.as of 05 May 2023 | 30.00m | 2.83% |
| Hargreaves Lansdown Fund Managers Ltd.as of 03 Nov 2025 | 26.60m | 2.51% |
| Coutts & Co. (Private Banking)as of 03 Nov 2025 | 14.43m | 1.36% |
| Dowgate Capital Ltd.as of 03 Nov 2025 | 12.70m | 1.20% |
| Rahn+Bodmer Co.as of 03 Nov 2025 | 11.54m | 1.09% |
| IG Markets Ltd.as of 03 Nov 2025 | 10.83m | 1.02% |
| Killik & Co. LLPas of 05 May 2023 | 10.62m | 1.00% |
| Rathbones Investment Management Ltd.as of 03 Nov 2025 | 3.37m | 0.32% |
